Delivery Order SPE2DB22D3501-SPE2DB25FWR23
- Not listed
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $10,146.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a Delivery Order valued at $10,256.76 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, firm fixed-price contract requires delivery by July 23, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The award carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA....
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency awarded a $28,192.03 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 22, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $16,050.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. The order, which was not set-aside, will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWR23Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $21,925.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order is non-competitive and carries no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. This delivery order fulfills immediate medical supply requirements for the Defense Health Agency and other Department of Defense healthcare beneficiaries under the broader pharmaceutical prime vendor global contract framework that DLA Troop Support maintains to ensure efficient, worldwide pharmaceutical support for military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.9k | 7/30/25 |